Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer

BACKGROUND: Recent approvals of gene therapies by the FDA and the EMA for treatment of inherited disorders have further opened the door for assessment of nucleic acid pharmaceuticals for clinical usage. Arising from the presence of damaged or inappropriate DNA, cancer is a condition particularly sui...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrudden, Cian M., McBride, John W., McCaffrey, Joanne, McErlean, Emma M., Dunne, Nicholas J., Kett, Vicky L., Coulter, Jonathan A., Robson, Tracy, McCarthy, Helen O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982451/
https://www.ncbi.nlm.nih.gov/pubmed/29899810
http://dx.doi.org/10.1186/s12645-018-0040-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982451/
https://www.ncbi.nlm.nih.gov/pubmed/29899810
http://dx.doi.org/10.1186/s12645-018-0040-x

Ejemplares similares